D2 vs D3 Lymph Node Dissection for Left Colon Cancer
Recruiting · NCT04364373 · Interventional (participants receive a specific treatment) · Lead sponsor: Russian Society of Colorectal Surgeons
View the official record on ClinicalTrials.gov →Interventions studied
Distal sigmoid colon resection or anterior resectionLeft colon resectionSigmoid colon resection
What this trial is about
The efficiency of the D3 lymph node dissection is still controversial for left colon cancer patients. This study will try find difference in 5-year overall survival between D2 and D3 lymph node dissection. Investigation of the functional and short-term outcomes will clarify safety of the D3 lymph node dissection.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Agreement of the patient to participate in trial
- Colon cancer (only adenocarcinoma )
- The tumor located between the splenic flexure and rectosigmoid junction
- cT3-Т4а,b
- cN0-2
- cM0
- Tolerance of chemotherapy
- ASA 1-3
Exclusion criteria
- сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder)
- Preoperative complications of the tumor (perforation and full bowel 3. obstruction)
- Previous radiotherapy or chemotherapy
- Synchronous or metachronous tumors
- Women during Pregnancy or breast feeding period
Where it is running
1 location listed.
- Clinic of coloproctology and minimally invasive surgery - Moscow, Russia